An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
Led by Dr Dan Worthley, Associate Professor Susan Woods and Dr Josephine Wright from SAHMRI and the University of Adelaide, in partnership with Professor Jeff Hasty at the University of California San Diego (UCSD), the study was published today in the prestigious journal, Science.
The team engineered bacteria called Acinetobacter baylyi (A. baylyi), which is known for its ability to sample and integrate DNA from its environment. Researchers leveraged this natural competence to detect the mutated KRAS gene, an important driver of colorectal cancer.
A/Prof Woods says they dubbed this technology ‘CATCH’, which stands for, Cellular Assay of Targeted CRISPR-discriminated Horizontal gene transfer.
“CATCH has the potential to detect bowel cancer early with the aim of preventing more people from dying of this and other cancers,” she said.
“This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places.”
In preclinical testing, the team found that the sensor bacteria were 100% accurate in differentiating between models with and without colorectal cancer.
“We were thrilled to see transfer of DNA from the tumour to the sensor bacteria,” A/Prof Woods said.
“This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem.”
Dr Dan Worthley says potential applications of the technology extend beyond cancer.
“In the future we will detect and prevent many diseases, including bowel cancer, with cells, not drugs,” he said.
“We hope that this invention, of life detecting life, will be useful for clinicians, scientists and engineers to help the community wherever and whenever DNA detection is important.”.
While further studies are needed before progressing to clinical trials, researchers are confident this latest discovery represents a significant advance in the field of living diagnostics while setting the stage for the timely and accurate delivery of targeted treatments.
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
-
Brain ageing, dementia and psychiatric disorders
Professor Perminder Sachdev graduated from the All-India Institute of Medical Sciences, New Delhi, in 1978 and completed his MD in Psychiatry there in 1983. Following time in New Zealand, he relocated to Australia, where he completed psychiatric training and a PhD at UNSW in 1991. His doctoral work examined ethnopsychological concepts in Māori culture. His early research focused on drug-induced movement disorders, including akathisia, tardive dyskinesia and neuroleptic malignant syndrome, while his later work has centred on dementia and pre-dementia syndromes, particularly neuroimaging, biomarkers and risk factors.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
